Sponsor or institution

Clinical trials and research at Novo Nordisk A/S

• 70Clinical trials
• 2New in 30 days
• 53Countries

Newest trials

All recruiting trials (70)

• Kidney and Heart Health in Adults with Type 2 Diabetes and CKD Treated with Semaglutide in China

  This study tests whether semaglutide injections help kidney and heart health in adults with type 2 diabetes and chronic kidney disease.

  Recruiting Phase 4 Novo Nordisk A/S · Fuyang, Anhui and 25 other locations · NCT07900438

• Safety test of NNC9836-0001 in adults with overweight/obesity or type 2 diabetes

  This study tests whether the new medicine NNC9836-0001 is safe and tolerable in adults who are overweight or have type 2 diabetes, compared to placebo.

  Recruiting Phase 1 Novo Nordisk A/S · Neuss · NCT07896109

• Switching to Zenagamtide From Tirzepatide in Adults With Overweight or Obesity With or Without Type 2 Diabetes

  This study tests whether adults who are overweight or have obesity (with or without type 2 diabetes) can switch from tirzepatide to a new treatment called zenagamtide to find a tolerable dose.

  Recruiting at 2 sites Phase 1 Novo Nordisk A/S · Glendale, California and 1 other locations · NCT07868354

• Switching to Zenagamtide from Semaglutide in adults with overweight or obesity, with or without type 2 diabetes

  This study tests whether adults who are already taking semaglutide can successfully switch to zenagamtide at different doses to see which dose works best.

  Recruiting at 2 sites Phase 1 Novo Nordisk A/S · Glendale, California and 1 other locations · NCT07855133

• Denecimig (Mim8) for adults with acquired Haemophilia A

  This study tests whether denecimig can be safe and helpful for adults newly diagnosed with acquired Haemophilia A.

  Recruiting Phase 3 Novo Nordisk A/S · Iowa City, Iowa and 82 other locations · NCT07830732

• New medicine NNC0642-1895 safety test in healthy adults

  This study tests a new medicine in healthy adults to see if it is safe and how it behaves in the body, comparing it to a placebo after a single dose.

  Recruiting Phase 1 Novo Nordisk A/S · Salt Lake City, Utah · NCT07829406

• Amaze 10: Testing NNC0487-0111 for Weight Loss in Japan

  This study tests whether the medicine NNC0487-0111 helps adults in Japan who are overweight or have obesity lose weight, compared with a placebo.

  Recruiting at 15 sites Phase 3 Novo Nordisk A/S · Sapporo, Hokkaido and 25 other locations · NCT07822061

• Switching from Semaglutide to CagriSema in Type 2 Diabetes

  This study tests whether people with type 2 diabetes can safely switch from branded semaglutide to CagriSema over about six months.

  Recruiting at 37 sites Phase 3 Novo Nordisk A/S · Gilbert, Arizona and 39 other locations · NCT07817251

• How meal timing and water amount affect how Zenagamtide is absorbed

  This study tests whether taking Zenagamtide with different meals and water amounts changes how the medicine enters the bloodstream in adults who are overweight or have obesity.

  Recruiting Phase 1 Novo Nordisk A/S · Berlin · NCT07815067

• A safe test of a new medicine for healthy adults

  This study tests a new medicine called NNC0705-0002 in healthy adults to see if it is safe and how it behaves in the body.

  Recruiting Phase 1 Novo Nordisk A/S · Groningen · NCT07797855

• Zenagamtide vs insulin glargine in type 2 diabetes with heart risk

  This trial tests whether weekly injections of zenagamtide can lower blood sugar and body weight better or differently than insulin glargine in people with type 2 diabetes and high cardiovascular risk who are on 1–3 other diabetes medicines.

  Recruiting at 56 sites Phase 3 Novo Nordisk A/S · Birmingham, Alabama and 329 other locations · NCT07797335

• Oral semaglutide for weight loss in adults who are overweight or have obesity

  This study tests whether lower doses of oral semaglutide can help adults with overweight or obesity lose weight, compared with a placebo.

  Recruiting at 55 sites Phase 3 Novo Nordisk A/S · Birmingham, Alabama and 61 other locations · NCT07770841

• Tolerability of Injecting Larger Volumes Subcutaneously at Different Speeds

  This study tests whether injecting larger volumes (2–5 mL) under the skin at different speeds is tolerable in healthy adults.

  Recruiting Phase 1 Novo Nordisk A/S · Gentofte Municipality · NCT07769489

• First-in-human look at how NNC0721-8060 works in people who are overweight or obese

  This early study tests whether NNC0721-8060 is safe and how it behaves in adults with overweight or obesity.

  Recruiting Phase 1 Novo Nordisk A/S · Lenexa, Kansas and 1 other locations · NCT07767175

• How a new drug (NNC0487-0111) changes energy use after weight loss in adults who are overweight or have obesity

  This study tests whether NNC0487-0111 changes how much energy the body uses after weight loss, compared with a low-calorie diet or placebo.

  Recruiting at 2 sites Phase 1 Novo Nordisk A/S · Aarhus N and 1 other locations · NCT07757087

• Two versions of an injectable medicine for people with excess weight, plus placebo

  This phase 3 trial tests whether cagrilintide helps adults with overweight or obesity lose weight compared to placebo.

  Recruiting at 35 sites Phase 3 Novo Nordisk A/S · Conyers, Georgia and 35 other locations · NCT07745504

• Zenagamtide for weight loss in adults with overweight or obesity

  This study tests whether Zenagamtide tablets help adults with excess body weight lose weight compared with placebo.

  Recruiting at 39 sites Phase 3 Novo Nordisk A/S · Anniston, Alabama and 40 other locations · NCT07720271

• How UBT251 Changes Levels of Midazolam, Caffeine, and Warfarin in People with Overweight or Obesity

  This study tests whether UBT251 can be safely used with common medicines like midazolam, caffeine, and warfarin in adults who are overweight or obese.

  Recruiting Phase 1 Novo Nordisk A/S · Cypress, California · NCT07710768

• How UBT251 works with birth control pills in women who are overweight or obese

  This study tests whether UBT251, taken with oral contraceptives and with an added option of acetaminophen, is safe and effective for women who are overweight or obese and unable to become pregnant.

  Recruiting Phase 1 Novo Nordisk A/S · Montreal, Quebec · NCT07710729

• New medicine NNC6022-0004 safety in healthy people and adults with obesity

  This study tests whether NNC6022-0004 is safe and tolerable in healthy adults and in adults with obesity, comparing it to placebo.

  Recruiting Phase 1 Novo Nordisk A/S · Groningen · NCT07693868

• MASLD care: how Chinese physicians diagnose and manage liver disease

  This survey asks Chinese doctors in major hospitals how they diagnose, assess fibrosis, and manage MASLD in patients with liver disease.

  Recruiting Novo Nordisk A/S · Beijing · NCT07682363

• Can Zenagamtide help people with excess weight lose more than Semaglutide

  This study tests whether Zenagamtide can help adults with overweight or obesity lose weight more effectively than Semaglutide or placebos.

  Recruiting at 33 sites Phase 3 Novo Nordisk A/S · Lancaster, California and 44 other locations · NCT07668414

• Testing different doses of UBT251 to lower blood sugar in adults with type 2 diabetes

  This study tests whether different doses of UBT251, compared with placebo and a standard diabetes medicine (semaglutide), can safely lower blood sugar in adults with type 2 diabetes.

  Recruiting at 58 sites Phase 2 Novo Nordisk A/S · Birmingham, Alabama and 69 other locations · NCT07668388

• How CDR132L enters the bloodstream after under-the-skin vs. vein injections

  This early-stage study tests how much CDR132L reaches the blood after skin injections compared with IV injections in healthy adults to guide dosing for people with heart failure.

  Recruiting Phase 1 Novo Nordisk A/S · Berlin · NCT07656454

• See if cagrilintide is tolerated in people with overweight or obesity who can't continue GLP-1-RA therapy due to GI side effects

  This study tests whether cagrilintide is safe and tolerated in adults with overweight or obesity who previously had GI side effects from GLP-1-RA medicines, compared with placebo, over about eight months.

  Recruiting at 10 sites Phase 1 Novo Nordisk A/S · Walnut Creek, California and 12 other locations · NCT07607587

• Two versions of cagrilintide in adults with overweight or obesity

  This study tests two versions of the drug cagrilintide to see how their blood levels compare in adults who are overweight or obese.

  Recruiting Phase 1 Novo Nordisk A/S · Berlin · NCT07597018

• Blood levels and tolerance of NNC0487-0111 in people with overweight/obesity and varying liver function

  This study tests a new medicine (NNC0487-0111) to see if it is safe and how it behaves in people with overweight or obesity, with or without liver impairment.

  Recruiting at 2 sites Phase 1 Novo Nordisk A/S · Bratislava and 1 other locations · NCT07587710

• Test of NNC0497-0040 in healthy adults, people with overweight/obesity, and adults with type 1 diabetes with overweight

  This study tests whether NNC0497-0040 is safe and tolerable and can help people who are healthy, those with overweight or obesity, and those with type 1 diabetes and overweight or obesity.

  Recruiting Phase 1 Novo Nordisk A/S · Neuss · NCT07578584

• NNC0487-0111 for weight loss and sleep apnea in adults with obesity and OSA on PAP

  A phase 3 study will test whether the medicine NNC0487-0111 helps adults who are overweight or have obesity and treated sleep apnea lose weight and improve sleep apnea symptoms compared with placebo.

  Recruiting at 82 sites Phase 3 Novo Nordisk A/S · Gilbert, Arizona and 91 other locations · NCT07571109

• Amazing weight loss and sleep apnea treatment with NNC0487-0111

  This study tests whether weekly injections of NNC0487-0111 help adults with overweight or obesity and sleep apnea who aren’t using CPAP to lose weight and improve breathing during sleep.

  Recruiting at 71 sites Phase 3 Novo Nordisk A/S · San Diego, California and 79 other locations · NCT07571005

• See if a new medicine NNC1679-0001 is safe in healthy people and in type 2 diabetes patients

  A new experimental medicine (NNC1679-0001) is being tested to see if it is safe and tolerated, compared with placebo, in healthy volunteers and adults with type 2 diabetes.

  Recruiting Phase 1 Novo Nordisk A/S · Graz · NCT07570992

• How well NNC0487-0111 works vs placebo in people with obesity and heart failure

  This study tests whether NNC0487-0111 can help people who have obesity and heart failure with preserved or mildly reduced ejection fraction, compared to placebo.

  Recruiting at 530 sites Phase 3 Novo Nordisk A/S · Alexander City, Alabama and 837 other locations · NCT07567001

• How a new medicine (NNC0113-5840) may help with overweight or obesity

  This study tests whether NNC0113-5840 is safe and working to help adults who are overweight or have obesity, compared to a placebo.

  Recruiting at 2 sites Phase 1 Novo Nordisk A/S · Glendale, California and 1 other locations · NCT07566390

• Two doses of CagriSema plus one dose of Semaglutide for weight loss in obesity with or without type 2 diabetes

  This study tests whether two doses of CagriSema, plus a dose of Semaglutide, help adults with obesity (with or without type 2 diabetes) lose weight.

  Recruiting Phase 3 Novo Nordisk A/S · Birmingham, Alabama and 302 other locations · NCT07564414

• How cagrilintide affects appetite and food intake in adults with overweight or obesity

  This study tests whether cagrilintide changes how much people with overweight or obesity eat compared with a placebo.

  Recruiting Phase 1 Novo Nordisk A/S · Berlin · NCT07557953

• How NNC0487-0111 affects insulin use and pancreas function in adults with type 2 diabetes

  This study will test whether a new drug called NNC0487-0111 changes how the body uses insulin and how the pancreas works in adults with type 2 diabetes who are on stable metformin (with or without an SGLT2 inhibitor).

  Recruiting Phase 1 Novo Nordisk A/S · Neuss · NCT07535307

• Cardiovascular risk profile in people newly diagnosed with type 2 diabetes in Southeast Asia

  This project will see how cardiovascular risk is distributed among people aged 40–69 who were newly diagnosed with type 2 diabetes and started treatment in Southeast Asia using medical records from the year before and the first year after diagnosis.

  Recruiting Novo Nordisk A/S · Tangerang, Banten and 5 other locations · NCT07532863

• Effect of CagriSema, cagrilintide, and semaglutide on muscle health during weight loss

  This trial tests whether CagriSema, cagrilintide, or semaglutide helps preserve muscle health as people aged 50-70 with obesity and mildly elevated blood sugar lose weight.

  Recruiting Phase 1 Novo Nordisk A/S · Aarhus N · NCT07527195

• Amaze 6: Testing NNC0487-0111 to help people with overweight and knee osteoarthritis lose weight and ease pain

  This study tests whether weekly injections of NNC0487-0111 help adults with overweight or obesity and knee osteoarthritis lose weight and reduce knee pain compared with a placebo.

  Recruiting at 74 sites Phase 3 Novo Nordisk A/S · Escondido, California and 80 other locations · NCT07509307

• How NNC0487-0111 affects appetite, food intake, and metabolism after meals in people with obesity

  This test will try whether weekly injections of NNC0487-0111 reduce appetite, lower how much adults with obesity eat after meals, and change their metabolism compared with a placebo.

  Recruiting Phase 1 Novo Nordisk A/S · Berlin · NCT07508020

• Weekly NNC0487-0111 injections for weight loss and knee pain in adults with excess weight and knee osteoarthritis

  This will try weekly NNC0487-0111 injections versus placebo to see if adults with excess body weight and knee osteoarthritis can lose weight and have less knee pain.

  Recruiting at 73 sites Phase 3 Novo Nordisk A/S · Phoenix, Arizona and 81 other locations · NCT07481630

• Coramitug PET/CT imaging to track and affect heart amyloid in ATTR-CM

  This study tests whether a radioactive version of the antibody coramitug can be detected in and displaced from heart amyloid in people aged 60 and older with transthyretin amyloid cardiomyopathy, and whether the drug is safe and well tolerated.

  Recruiting Phase 1 Novo Nordisk A/S · Groningen · NCT07448623

• Safety testing of NNC6989-0001 in adults with overweight or obesity

  This study will test whether the medicine NNC6989-0001 is safe and tolerable for adults who are overweight or have obesity.

  Recruiting Phase 1 Novo Nordisk A/S · Lenexa, Kansas · NCT07437079

• Different doses of NNC0662-0419 versus semaglutide and placebo to lower blood sugar in adults with type 2 diabetes

  This trial will test whether different doses of the experimental medicine NNC0662-0419 lower blood sugar in adults with type 2 diabetes compared with placebo or semaglutide.

  Recruiting at 50 sites Phase 2 Novo Nordisk A/S · Lancaster, California and 62 other locations · NCT07415954

• Weekly injections of GIP (NNC0480-0389) plus amylin (cagrilintide) to see stomach side effects in adults with overweight or obesity

  This trial tests whether adding a GIP injection (NNC0480-0389) to weekly cagrilintide changes stomach-related side effects in adults with overweight or obesity.

  Recruiting Phase 1 Novo Nordisk A/S · Harrow, Middlesex · NCT07411560

• Different doses of UBT251 for adults with overweight or obesity

  This trial will test whether different doses of UBT251 help adults with overweight or obesity by comparing the medicine to a placebo.

  Recruiting at 3 sites Phase 2 Novo Nordisk A/S · Cypress, California and 2 other locations · NCT07395687

• AMAZE 1: NNC0487-0111 for adults with excess body weight

  This trial tests whether weekly injections of NNC0487-0111 help adults with excess body weight lose weight compared with a placebo.

  Recruiting at 65 sites Phase 3 Novo Nordisk A/S · Miramar, Florida and 71 other locations · NCT07339423

• Ziltivekimab to reduce plaque in heart arteries after a heart attack

  This trial will test whether ziltivekimab can reduce plaque in the heart's blood vessels in adults who recently had a heart attack.

  Recruiting at 3 sites Phase 3 Novo Nordisk A/S · Vienna and 19 other locations · NCT07301034

• CagriSema vs placebo in children and teens with Type 2 diabetes

  This study tests whether CagriSema helps lower blood sugar and reduce body weight in kids and teens with Type 2 diabetes, compared with placebo in the first phase and then all participants receive CagriSema in the second phase.

  Recruiting at 31 sites Phase 3 Novo Nordisk A/S · New Haven, Connecticut and 57 other locations · NCT07282613

• NNC9733-0001 for adults with type 2 diabetes and healthy volunteers

  This study will try a single injected dose of NNC9733-0001 to see if it is safe, well tolerated, and lowers blood sugar in adults with type 2 diabetes, with healthy volunteers included for comparison.

  Recruiting Phase 1 Novo Nordisk A/S · Neuss · NCT07270731

• CagriSema and cagrilintide for weight loss in children and teens with excess body weight

  This study will see if CagriSema or cagrilintide help children and teens (ages 8 to under 18) with excess body weight lose weight compared with semaglutide or a placebo.

  Recruiting at 65 sites Phase 3 Novo Nordisk A/S · Escondido, California and 120 other locations · NCT07253285

• How fasting time and briefly stopping GLP-1 medicines change how much food stays in the stomach for people on liraglutide or semaglutide

  This trial will test whether different fasting durations and a short pause in GLP-1 medications change how much food remains in the stomach for adults taking liraglutide or semaglutide.

  Recruiting Phase 1 Novo Nordisk A/S · Cypress, California · NCT07225816

• Different doses of Inno8 for adults with haemophilia A.

  This trial will test different doses of the experimental medicine Inno8 in adults with haemophilia A to see if it is safe and how the body handles it.

  Recruiting at 25 sites Phase 1 Novo Nordisk A/S · Aurora, Colorado and 32 other locations · NCT07220564

• Effects of NNC0537-1482 in people with heart failure

  This trial will test whether the new drug NNC0537-1482 is safe and how it works in adults aged 40-75 with symptomatic heart failure.

  Recruiting Phase 1 Novo Nordisk A/S · London · NCT07218627

• Coramitug (NNC6019-0001) for heart failure from transthyretin amyloid cardiomyopathy

  This study tests whether coramitug (NNC6019-0001) can lower the risk of heart-related death and illness in adults with transthyretin amyloid cardiomyopathy (ATTR-CM) while they continue their usual heart medicines.

  Recruiting at 237 sites Phase 3 Novo Nordisk A/S · Phoenix, Arizona and 298 other locations · NCT07207811

• Eptacog alfa to stop heavy bleeding after childbirth in India

  This will test whether the medicine eptacog alfa can safely stop severe bleeding in women in India after childbirth.

  Recruiting at 8 sites Phase 4 Novo Nordisk A/S · Belagavi, Karnataka and 13 other locations · NCT07157423

• Safety follow-up after INV-347 dosing in INV-CL-108

  This follow-up checks the safety and blood levels of INV-347 in adults who previously received INV-347 in INV-CL-108.

  Recruiting Phase 1 Novo Nordisk A/S · Québec · NCT07153172

• Once-weekly insulin icodec versus daily basal insulin for adults with type 2 diabetes

  This test looks at whether a once-weekly injectable insulin (icodec) can keep blood sugar as well as commonly used daily basal insulins in adults with type 2 diabetes who need basal insulin.

  Recruiting at 58 sites Phase 4 Novo Nordisk A/S · Calgary, Alberta and 74 other locations · NCT07112339

• Cagrilintide's effect on bone health during weight loss in postmenopausal women with obesity

  This trial will test whether the medicine cagrilintide helps protect bone mass during weight loss in postmenopausal women with obesity compared with semaglutide or placebo.

  Recruiting Phase 1 Novo Nordisk A/S · Herlev · NCT07010432

• CDR132L versus placebo to improve heart structure and function in people with heart failure and left ventricular hypertrophy

  This trial will try CDR132L to see if it improves heart structure and function compared with placebo in people aged 40–84 who have chronic heart failure with reduced or mildly reduced ejection fraction and left ventricular hypertrophy.

  Recruiting at 64 sites Phase 2 Novo Nordisk A/S · Concord, New South Wales and 91 other locations · NCT06979375

• Different doses of CDR132L versus placebo for heart structure and function in people with HFpEF and left ventricular hypertrophy

  This study will test whether different doses of CDR132L can improve heart structure and function in people with heart failure with preserved ejection fraction and left ventricular hypertrophy.

  Recruiting at 78 sites Phase 2 Novo Nordisk A/S · Birmingham, Alabama and 117 other locations · NCT06979362

• New medication for treating liver diseases

  This study is testing a new medication for people with liver diseases to see if it is safe and helps reduce liver fat and inflammation.

  Recruiting Phase 1 Novo Nordisk A/S · Harrow · NCT06891365

• Awiqli (insulin icodec) use and results in people with diabetes in Japan.

  This study will test Awiqli (insulin icodec) in people with diabetes to see if it's safe and works well during routine care in Japan.

  Recruiting at 25 sites Novo Nordisk A/S · Koriyama-shi, Fukushima, Fukushima, Japan and 115 other locations · NCT06807190

• Comparing doses of NNC0519-0130 for reducing kidney damage in chronic kidney disease patients

  This study is testing different doses of a new medication called NNC0519-0130 to see if it can help reduce kidney damage in people with chronic kidney disease, including those with type 2 diabetes.

  Recruiting at 16 sites Phase 2 Novo Nordisk A/S · San Dimas, California and 146 other locations · NCT06717698

• Evaluating Etavopivat for Sickle Cell Disease

  This study is testing if a new drug called etavopivat can help reduce painful crises and improve overall health in adults and teens with sickle cell disease.

  Recruiting at 130 sites Phase 3 Novo Nordisk A/S · Birmingham, Alabama and 174 other locations · NCT06612268

• Long-term treatment with Etavopivat for sickle cell disease and thalassemia

  This study is testing how safe and effective a new medication called Etavopivat is for people with sickle cell disease and thalassemia who have already seen benefits from it.

  Recruiting at 45 sites Phase 3 Novo Nordisk A/S · Birmingham, Alabama and 106 other locations · NCT06609226

• Evaluating DCR-PDL1 for adults with solid tumors

  This study is testing a new treatment called DCR-PDL1 given through an IV to see if it's safe and works for adults with solid tumors.

  Recruiting at 2 sites Phase 1 Novo Nordisk A/S · Irving, Texas and 1 other locations · NCT06504368

• Evaluating Etavopivat for Pediatric Sickle Cell Disease

  This study is testing a new oral medication called etavopivat in teenagers with sickle cell disease to see how it works in their bodies and if it helps them feel better over 96 weeks.

  Recruiting at 12 sites Phase 2 Novo Nordisk A/S · Toronto, Ontario and 17 other locations · NCT06198712

• Evaluating Etavopivat for Pediatric Sickle Cell Disease Patients at Risk for Stroke

  This study is testing if a new medication called etavopivat can help prevent strokes in kids aged 12 to 16 with sickle cell disease who are at higher risk.

  Recruiting at 4 sites Phase 2 Novo Nordisk A/S · Raipur, Chhattisgarh and 8 other locations · NCT05953584

• Evaluating DCR-PHXC for patients with Primary Hyperoxaluria Type 1 and severe kidney disease

  This study is testing a new treatment called DCR-PHXC to see if it can help people with Primary Hyperoxaluria Type 1 and severe kidney disease feel better.

  Recruiting at 6 sites Phase 2 Novo Nordisk A/S · San Francisco, California and 17 other locations · NCT04580420

Quick answers

How many clinical trials run by Novo Nordisk A/S are recruiting right now?

70, as of November 12, 2026. 2 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 53 countries. The most sites are in United States (36 trials), Germany (23 trials), Spain (21 trials), Poland (17 trials), Canada (16 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 34, Phase 3: 21, Phase 2: 9, Phase 4: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →